InvestorWire NewsRoom


Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Presentation to Provide Overview of Psychedelic Drug Candidate Program at Ladenburg Thalmann Healthcare Conference
June 16, 2021

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Presentation to Provide Overview of Psychedelic Drug Candidate Program at Ladenburg Thalmann Healthcare Conference

  • Tryp Therapeutics is a development-stage pharmaceutical company dedicated to finding novel bioscience solutions for conditions with unmet needs
  • The company’s executive team will present an overview of its Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program, in response to conditions such as fibromyalgia, at next month’s Ladenburg Thalmann Healthcare Conference
  • Tryp’s synthetic psychedelic drug candidate will be further developed in an upcoming phase 2a clinical study in partnership with pediatric eating disorders expert Jennifer Miller, M.D. at the University of Florida
  • The trial will focus on Tryp’s flagship candidate, TRP-8802, in treating binge eating and hypothalamic obesity
  • The company expects to begin manufacturing its initial oral psilocybin formulation in September

Bio-pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) will present an overview of Tryp’s efforts to develop a novel psychedelic drug candidate for treating fibromyalgia and other neuropsychiatric-based disorders at the annual Ladenburg Thalmann Healthcare Conference next month.

Ladenburg Thalmann & Co. Inc. is an experienced provider of investment banking and capital markets products and services. The Ladenburg Thalmann Healthcare Conference is a well-respected event for investors who are specifically focused on healthcare and life sciences companies, and will be held virtually on July 13 and 14, with Tryp’s presentation taking place July 13 at 3 p.m. EDT ( 

In 2021, fibromyalgia remains an elusive medical condition difficult to verify and treat 45 years after it was first used as a term to describe century-old observations of patients’ complaints of chronic widespread pain and fatigue. 

The first clinical, controlled study of fibromyalgia symptoms was only published as recently as 1981 and trials for the first proposed medications to treat it were subsequently announced in 1986. At present, all forms of diagnosis involve first ruling out other potential causes and verifying that a set number of symptoms exist, and the challenge of treating it results in a range of recommendations from “getting enough sleep and exercise” to using opioid pain drugs ( 

Efforts to diagnose fibromyalgia and consequently treat it may be improved thanks to numerous ongoing efforts to develop a blood test that will recognize its presence. In May, researchers at the Ohio State University Wexner Medical Center claimed to have developed the first potentially successful blood test for diagnosing fibromyalgia, according to media reports ( 

Tryp is developing its lead drug candidate, TRP-8802, as a potentially novel drug class solution for treating certain neuropsychiatric-based disorders such as fibromyalgia, utilizing psychedelic substances tested under its Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program. 

Tryp’s mission is to use its novel solutions, including the PFN program, to develop compounds for treating diseases with high unmet medical needs.  

The company is also in the process of launching a Phase 2a clinical study using its TRP-8802 synthetic psilocybin Active Pharmaceutical Ingredient (“API”) to test for treatment of binge eating and hypothalamic obesity in partnership with pediatric eating disorders expert Jennifer Miller, M.D. and her team at the University of Florida. 

Tryp expects to manufacture its initial batch of orally available cGMP psilocybin API in September, which will then be analyzed for quality consistency to establish the final formulation of the oral psilocybin product.

The company’s executive team will discuss the company’s business and its pipeline at the Ladenburg Thalmann Healthcare Conference and then participate in a brief analyst-led discussion. 

Registration for the virtual event can be completed online at

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).